share_log

藥明生物：截至2024年3月31日止股份發行人的證券變動月報表

WUXI BIO: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024

香港交易所 ·  Apr 2 21:21
Summary by Futu AI
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，普通股股份數目仍為6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，公司於2024年3月通過行使股份期權計劃新增238,000股普通股，並因此獲得資金總額為71,801.3美元。同時，公司於2023年12月至2024年3月期間購回並尚未註銷的普通股總數為85,907,000股。藥明生物確認，所有新發行的證券均已獲得董事會的正式授權和批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
藥明生物（WuXi Biologics (Cayman) Inc.）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本維持不變，普通股股份數目仍為6,000,000,000股，每股面值為USD1/120,000，法定/註冊股本總額為50,000美元。此外，公司於2024年3月通過行使股份期權計劃新增238,000股普通股，並因此獲得資金總額為71,801.3美元。同時，公司於2023年12月至2024年3月期間購回並尚未註銷的普通股總數為85,907,000股。藥明生物確認，所有新發行的證券均已獲得董事會的正式授權和批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on April 2, 2024 its latest Securities Changes Monthly Report, reporting the changes in the company's shares for the year ended March 31, 2024. The report showed that the company's regulary/registered share capital remained unchanged, with the number of ordinary shares remaining at 6,000,000,000 shares, with a face value of USD1/120,000 and a total regulated/registered share capital of $50,000. In addition, the company added 238,000 shares of common stock through the exercise of the share option program in March 2024, resulting in a total capital of $71,801.3. At the same time, the total number of ordinary shares repurchased and not written off by the Company from December 2023 to March 2024 is 85,907,000 shares. Pharmacio confirms that all newly issued securities have been formally authorized and approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
WuXi Biologics (Cayman) Inc. (WuXi Biologics (Cayman) Inc.) filed with Hong Kong Trading and Clearing Limited on April 2, 2024 its latest Securities Changes Monthly Report, reporting the changes in the company's shares for the year ended March 31, 2024. The report showed that the company's regulary/registered share capital remained unchanged, with the number of ordinary shares remaining at 6,000,000,000 shares, with a face value of USD1/120,000 and a total regulated/registered share capital of $50,000. In addition, the company added 238,000 shares of common stock through the exercise of the share option program in March 2024, resulting in a total capital of $71,801.3. At the same time, the total number of ordinary shares repurchased and not written off by the Company from December 2023 to March 2024 is 85,907,000 shares. Pharmacio confirms that all newly issued securities have been formally authorized and approved by the Board of Directors and comply with the relevant requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.